Category: 3. Business

  • Ryanair says it could use Starlink in future despite Elon Musk feud | Ryanair

    Ryanair says it could use Starlink in future despite Elon Musk feud | Ryanair

    Ryanair would be open to using Elon Musk’s Starlink wifi on its planes in the future, its finance chief has suggested, amid a feud between the boss of the Irish airline and the world’s richest person.

    The airline would look at “whoever is the best, when the tech and price is right” for in-flight wifi, the Ryanair chief financial officer, Neil Sorahan, said.

    Sorahan was speaking after an online spat between Ryanair boss Michael O’Leary and Musk, after O’Leary was asked whether he would follow Lufthansa and British Airways in installing Starlink satellite internet technology on his fleet of 650 aircraft.

    The chief executive rejected the idea, saying that adding antennas to the jets would result in a “2% fuel drag”, adding an extra $200-250m to its $5bn (£3.66bn) annual kerosene bill.

    Musk said the interpretation was “misinformed” in a post on his X platform, triggering a tit-for-tat exchange of insults, with each man calling the other an “idiot”.

    Sorahan said the spat was “good fun” and had brought more people to the Ryanair website. O’Leary said last week that his quarrel with Musk had increased bookings by between 2% and 3%, after the company pushed a “big idiot sale” campaign poking fun at the Tesla chief executive, estimated to be worth $788bn by Forbes.

    However, Sorahan added that in-flight wifi was still a long way away for Ryanair. “I have been looking at wifi for as long as I have been at Ryanair,” said the executive, who joined the airline in 2003. “There is still a fuel cost that we would have to absorb.”

    There are concerns passengers may be less willing to pay for wifi on Ryanair’s short-haul flights, which typically only take between one and three hours.

    The airline, which has grown to become the biggest in Europe, raised its forecasts for passenger numbers, profit growth and fares on Monday. It now expects to carry 216 million passengers by March 2027, and said average fares this year would rise by 7% to 8%, compared with previous guidance of 7%. Average fares rose 4% to €44 (£38) in its third quarter to the end of December.

    Its profit after tax fell 22% to €115m in the third quarter, excluding a provision of €85m for a fine from the Italian competition authority, which the company said it was appealing against. However, it expects profit after tax between €2.13bn and €2.23bn for its full year.

    The airline said Boeing deliveries were progressing well compared with a year ago when the aircraft supplier struggled to deliver jets on time. It said the final four Max 8 models would be delivered by the end of February, while the newer Max 10 would join the Ryanair fleet in spring 2027.

    Shares in Ryanair, which are listed in Dublin and New York, dropped 1.7% in early European trading on Monday. They rose by more than 50% over the course of last year.

    Continue Reading

  • Property cat reinsurance softening to continue into April, June and July renewals, says Fitch

    Property cat reinsurance softening to continue into April, June and July renewals, says Fitch

    With property catastrophe reinsurance rates significantly softening at the January 2026 renewals, rating agency Fitch forecasts that further softening will continue into the April, June, and July renewals later this year.

    At the same time, the agency confirmed that it is maintaining its ‘deteriorating’ sector outlook for global reinsurance in 2026, citing moderately weaker operating and business conditions expected over the year.

    Fitch adjusted its outlook for the global reinsurance industry to “deteriorating” from “neutral” back in September, with the agency saying at the time that “Softer pricing conditions and rising claims costs will pressure underwriting margins, though profitability remains strong by historical standards.”

    Analysts at Fitch recently highlighted how record amounts of reinsurance capital supply from both traditional and alternative sources exceeded the slight demand increase from buyers during the January 1, 2026 renewals, which drove a softening market, but one that analysts feel can still deliver profits.

    “Property catastrophe pricing significantly softened at the January 2026 reinsurance renewals following rate reductions at the mid-year 2025 renewals, with reductions in risk-adjusted prices across most lines,” Fitch said.

    Rate reductions of up to 5% were observed for US and European catastrophe-exposed portfolios, while for loss-free US property business, pricing declines reached as much as 20%, compared with a range of down 10% to up 10% from the previous year.

    Additionally, European property rates also fell by up to 20% for loss-free accounts at the January renewals, versus a range of down 15% to up 5% in 2025.

    As mentioned, the rating agency expects to see these softening conditions continue throughout 2026.

    “We anticipate softening market conditions to continue at the midyear 2026 renewals in April (Asia-focused) and June/July (Florida). Abundant capacity and rising competition are likely to lead to gradual price erosion across most reinsurance lines and looser policy terms in property lines, barring large loss activity,” Fitch explained.

    Fitch also outlined that competitive behaviour remains rational and disciplined, with loss ratios continuing to benefit from favourable claims frequency trends.

    Moreover, while severe hurricane-related events and other natural catastrophe losses remain a key source of volatility for P&C insurers, Fitch Ratings believes the sector is well capitalised to withstand large single-event losses.

    However, the agency warned that a series of major catastrophic events occurring in quick succession could strain capital positions and result in adverse rating consequences.

    “Fitch has a ‘neutral’ fundamental sector outlook for the US property/casualty (P&C) insurance sector in 2026, as well as for both commercial and personal lines. Our ‘deteriorating’ outlook for the global reinsurance sector for 2026 reflects that underlying operational and business conditions are likely to worsen overall for reinsurers globally,” Fitch concluded.

    Print Friendly, PDF & Email

    Continue Reading

  • FX Daily: Suspected USD/JPY intervention adds to weak dollar moment | articles

    FX Daily: Suspected USD/JPY intervention adds to weak dollar moment | articles

    Suspected Japanese intervention to sell USD/JPY has come at a weak time for the dollar after last week’s geopolitical fracturing. From what we understand so far, Japanese authorities may have intervened on Friday when USD/JPY pushed above 159 after the Bank of Japan policy meeting. The big kicker, however, was widespread discussion that at the London close at 17:00 GMT on Friday, the Federal Reserve started asking banks in New York about their position sizes in USD/JPY. This was seen as akin to a ‘rate check’, where a central bank might be preparing the market for physical intervention. That the Fed was allegedly doing this and not making clear that this activity was purely on behalf of Japanese authorities – i.e., that the Fed was not acting purely as an ‘agent’ – has led to understandable suggestions that the US might be on the verge of joint intervention with Japan. This is something we discussed in this month’s FX Talking.

    The prospect of bilateral Japan-US intervention is understandably a more powerful one than mere passive intervention from Tokyo alone. Why would Washington want to get involved? We see two reasons: a) the weak yen was adding to last week’s JGB sell-off and indirectly driving US Treasury yields higher. If there is any financial instrument more important than the stock market to the White House right now, it is US Treasuries. And b) the strong USD/JPY was potentially unwinding the work of US tariffs on Japan and giving Japanese manufacturers a competitive advantage.

    However, this is not a fundamentally driven move. Yen real interest rates are still negative, and the snap Japanese election on 8 February could still see more pressure emerge on JGBs and the yen. And away from the geopolitical risk premium being attached to US assets, the dollar’s fundamental story has not deteriorated. Plus, we suspect this week’s FOMC meeting could prove slightly dollar bullish.

    No doubt, Japanese and potentially US authorities, too, like this constructively ambiguous approach to FX intervention. Traders will be bracing for activity at both market opens and closes now. An upside gap in USD/JPY at 155.65 may now prove intraday resistance. But for the dollar sell-off to continue like this, we will probably need to see some poor domestic US news. Away from the FOMC, this will heighten scrutiny on earnings releases from US Big Tech this Wednesday and Thursday.

    This yen intervention story has weighed heavily on DXY, where the prospect of up to $100bn of sales (that’s what Tokyo sold in summer 2024) has caught the dollar at a weak moment. DXY has an upside gap to 97.42 (now resistance) and has a bias to last year’s lows at 96.20/35 – but really needs some fundamental backing for these moves to sustain.

    Chris Turner

    Continue Reading

  • CVC acquires leading US credit manager Marathon Asset Management (“Marathon”)

    CVC acquires leading US credit manager Marathon Asset Management (“Marathon”)

    Bruce Richards, Co-Founder of Marathon, said: “For 28 years, Marathon’s unwavering mission is to deliver exceptional investment performance for clients through our robust origination platform, rigorous investment approach, deep specialization, and disciplined risk-management. CVC’s focus on delivering exceptional investment returns, integrity, collaboration, and client partnership closely aligns with Marathon’s culture. CVC’s global reach and its investment insights across multiple asset classes and geographies will deliver a powerful partnership, and we greatly look forward to growing our world class credit platform together with CVC.”

    The $1.2 billion closing consideration comprises $400 million in cash and up to $800 million in CVC equity2. The transaction also includes earn-out consideration linked to Marathon’s future financial performance over the period from FY2027 to FY2029, of up to $200 million in cash and $200 million in CVC equity2.

    The acquisition is expected to be EPS neutral in 2027 and EPS accretive from 2028 onwards, before any revenue or cost synergies.

    Bruce Richards and Lou Hanover will continue to co-head the Marathon credit strategies, and Marathon will be re-branded CVC-Marathon.

    Bruce Richards will join the Partner Board of CVC, and alongside Andrew Davies, will be responsible for managing the combined CVC Credit business. 

    The transaction is subject to regulatory and other consents and is expected to close in Q3 2026.  Advisers to CVC included JP Morgan, Freshfields, Fried Frank and Ernst & Young. Advisers to Marathon included Sidley Austin.

    Transaction details

    CVC will acquire 100% of Marathon in a cash and equity transaction with a base consideration valued at up to $1.2 billion, comprising consideration at closing of $400 million in cash and up to 45 million units of equity to be issued by a wholly-owned subsidiary of CVC (“SubCo Units”), exchangeable on a one-for-one basis into CVC ordinary shares, subject to customary completion accounts adjustments and, in respect of 11 million SubCo Units, FY 2027 Marathon financial performance adjustments.  

    The transaction also includes earn-out consideration linked to Marathon’s future financial performance over the period from FY 2027 to FY 2029, of up to $200 million of cash and 11 million SubCo Units. The earn-out consideration is only payable to Marathon’s partners and employees, increasing long-term alignment and continuity across a broader group. Marathon’s minority partner will receive $280 million of the cash consideration portion of the transaction for 100% of their interest in Marathon.

    CVC ordinary shares issued in exchange for any SubCo Units will be held subject to substantially the same lock-up restrictions entered into by CVC’s current and former employees (and permitted transferees) as part of CVC’s IPO in April 2024. The cash portion of the transaction will be funded from CVC’s current cash on balance sheet and undrawn credit facilities.

     

    1 As at 30 September 2025.

    2  The CVC equity will be issued by a wholly-owned CVC subsidiary and will be exchangeable on a one-for-one basis into CVC ordinary shares.

    Continue Reading

  • Canon’s sustainability efforts recognized with top 1% Platinum rating from global sustainability ratings organization EcoVadis for second consecutive year

    Canon’s sustainability efforts recognized with top 1% Platinum rating from global sustainability ratings organization EcoVadis for second consecutive year

    Canon’s sustainability efforts recognized with top 1% Platinum rating from global sustainability ratings organization EcoVadis for second consecutive year

    TOKYO, January 26, 2026—Canon Inc. announced today that the company has been awarded the Platinum rating for the second consecutive year for its sustainability efforts by France-based global sustainability ratings organization EcoVadis. The award places Canon within the top 1% of companies assessed globally.

    EcoVadis assesses over 150,000 companies spanning 185 countries and 250 industries according to various criteria across the four themes of “Environment,” “Labor & Human Rights,” “Ethics” and “Sustainable Procurement.” As worldwide interest in corporate sustainability efforts increases, companies around the world now take into consideration the EcoVadis rating of potential clients and partners.

    The Canon Group has made continued efforts toward sustainability, which led to high rankings in all four categories. Canon received particularly high marks in the categories of “Environment” and “Labor & Human Rights” which helped it to obtain the Platinum rating for a second consecutive year.

    Canon’s initiatives for sustainability

    Canon is working to strengthen initiatives related to environmental and societal issues in order to contribute to societal sustainability.

    In the environmental field, Canon aims to achieve net-zero greenhouse gas (GHG) emissions throughout entire product life cycles (Scope 1, 2, and 3) by 2050.1 Canon has also set science-based GHG emissions reduction targets in line with SBTi standards: by 2030, a 42% reduction in Scope 1 and 2 emissions and a 25% reduction in Scope 3 emissions (Category 1 and 11) compared to 2022 levels.2

    Furthermore, Canon respects the human rights of all stakeholders involved in its business activities, including employees and business partners. It has formulated the Canon Group Human Rights Policy as a declaration of its stance on human rights and implements human rights due diligence throughout the entire Group while carrying out activities to spread awareness among Group employees both in Japan and overseas through such methods as e-learning.

    • 1

      Scope 1: Direct emissions (city gas, LPG, diesel, kerosene, non-energy-related greenhouse gases, etc.); Scope 2: Indirect emissions (electricity, steam, etc.); Scope 3: Emissions in the supply chains. category 1: Purchased goods and services; category 11: Use of products sold.

    • 2

      The Science Based Targets initiative (SBTi) is a global initiative that encourages companies to set GHG reduction targets based on climate science. It is jointly operated by the UN Global Compact (UNGC), World Resources Institute (WRI), World Wide Fund for Nature (WWF), and the CDP.

    Continue Reading

  • 3 Asian Growth Companies With High Insider Ownership And 24% Earnings Growth

    3 Asian Growth Companies With High Insider Ownership And 24% Earnings Growth

    As global markets navigate a period of volatility and geopolitical uncertainty, the Asian market continues to present intriguing opportunities for investors, particularly in the realm of growth companies with high insider ownership. In this environment, stocks that demonstrate robust earnings growth and strong insider commitment can offer a compelling mix of potential stability and upside, making them noteworthy considerations for those looking to understand current trends in Asia’s evolving economic landscape.

    Name

    Insider Ownership

    Earnings Growth

    UTI (KOSDAQ:A179900)

    24.7%

    120.7%

    Streamax Technology (SZSE:002970)

    32.5%

    31.5%

    Phison Electronics (TPEX:8299)

    10.8%

    31.7%

    Novoray (SHSE:688300)

    23.6%

    31.4%

    Modetour Network (KOSDAQ:A080160)

    12.7%

    41.8%

    Loadstar Capital K.K (TSE:3482)

    31%

    23.6%

    Laopu Gold (SEHK:6181)

    34.8%

    34.1%

    Gold Circuit Electronics (TWSE:2368)

    31.4%

    37.5%

    FUNDINNOInc (TSE:462A)

    33.4%

    41.5%

    Fulin Precision (SZSE:300432)

    10.6%

    63.7%

    Click here to see the full list of 599 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.

    Below we spotlight a couple of our favorites from our exclusive screener.

    Simply Wall St Growth Rating: ★★★★☆☆

    Overview: MIXUE Group operates in the production and sale of fruit drinks, tea drinks, ice cream, and coffee products across Mainland China and internationally, with a market cap of HK$163.39 billion.

    Operations: The company’s revenue segments include Franchise and Related Services generating CN¥707.31 million, Sales of Goods contributing CN¥27.37 billion, and Sales of Equipment accounting for CN¥949.98 million.

    Insider Ownership: 28.8%

    Earnings Growth Forecast: 14.2% p.a.

    Mixue Group, a rapidly expanding entity with substantial insider ownership, is poised for growth with earnings projected to rise by 14.2% annually, outpacing the Hong Kong market. Despite not having significant insider trading activity recently, Mixue’s strategic expansion into the Americas signifies its commitment to global growth. The company opened its first U.S. store in Los Angeles and plans further expansion across New York, leveraging a robust supply chain and value-driven menu to capture international markets effectively.

    SEHK:2097 Ownership Breakdown as at Jan 2026

    Simply Wall St Growth Rating: ★★★★★☆

    Overview: Sieyuan Electric Co., Ltd. specializes in the research, development, production, sale, and service of power transmission and distribution equipment both in China and internationally, with a market cap of CN¥147.46 billion.

    Operations: The company’s revenue is primarily derived from the Distribution and Controls Equipment/Furniture segment, totaling CN¥21.21 billion.

    Insider Ownership: 35%

    Earnings Growth Forecast: 24.3% p.a.

    Sieyuan Electric’s recent financial performance highlights its growth potential, with sales increasing to CNY 21.21 billion and net income rising to CNY 3.16 billion for the year ending December 2025. Despite being dropped from the FTSE All-World Index, its earnings grew by a substantial 54.4% over the past year, with forecasts predicting continued revenue growth of 21.1% annually—outpacing the broader Chinese market rate of 14.7%.

    SZSE:002028 Earnings and Revenue Growth as at Jan 2026
    SZSE:002028 Earnings and Revenue Growth as at Jan 2026

    Simply Wall St Growth Rating: ★★★★★☆

    Overview: Shanghai Huace Navigation Technology Ltd. operates in the field of navigation and positioning technology, with a market cap of CN¥33.03 billion.

    Operations: Shanghai Huace Navigation Technology Ltd. generates its revenue from various segments, but specific segment details are not provided in the available text.

    Insider Ownership: 24.2%

    Earnings Growth Forecast: 24% p.a.

    Shanghai Huace Navigation Technology’s growth trajectory is bolstered by its high insider ownership, with earnings expected to grow significantly at 24% annually. The company recently launched the Apache 6 – 2026 Edition, an advanced Unmanned Surface Vessel for precise mapping applications. Despite a volatile share price and a high P/E ratio of 48.1x, its revenue growth forecast of 22.6% per year surpasses the Chinese market average, indicating robust expansion potential in diverse sectors like agriculture and marine surveying.

    SZSE:300627 Ownership Breakdown as at Jan 2026
    SZSE:300627 Ownership Breakdown as at Jan 2026

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

    Companies discussed in this article include SEHK:2097 SZSE:002028 and SZSE:300627.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Amanat Holdings PJSC And 2 Other Undiscovered Gems In The Middle East

    Amanat Holdings PJSC And 2 Other Undiscovered Gems In The Middle East

    The Middle East markets have recently experienced fluctuations, with UAE indices dipping due to renewed geopolitical tensions, even as Dubai’s market had previously reached a near 20-year high. Amidst this backdrop of volatility and opportunity, identifying stocks that show resilience and potential for growth is crucial for investors looking to navigate these dynamic conditions.

    Name

    Debt To Equity

    Revenue Growth

    Earnings Growth

    Health Rating

    Nofoth Food Products

    NA

    21.36%

    25.28%

    ★★★★★★

    Sure Global Tech

    NA

    10.11%

    15.42%

    ★★★★★★

    Payton Industries

    NA

    3.44%

    14.24%

    ★★★★★★

    Analyst I.M.S. Investment Management Services

    NA

    31.20%

    44.24%

    ★★★★★★

    Najran Cement

    14.49%

    -4.20%

    -30.16%

    ★★★★★★

    Sönmez Filament Sentetik Iplik ve Elyaf Sanayi

    NA

    54.80%

    42.62%

    ★★★★★☆

    Gür-Sel Turizm Tasimacilik ve Servis Ticaret

    4.69%

    36.04%

    53.41%

    ★★★★★☆

    Segmen Kardesler Gida Üretim ve Ambalaj Sanayi Anonim Sirketi

    1.30%

    7.24%

    65.07%

    ★★★★☆☆

    Ajman Bank PJSC

    53.89%

    16.11%

    18.02%

    ★★★★☆☆

    Bosch Fren Sistemleri Sanayi ve Ticaret

    36.11%

    41.59%

    7.72%

    ★★★★☆☆

    Click here to see the full list of 185 stocks from our Middle Eastern Undiscovered Gems With Strong Fundamentals screener.

    Let’s dive into some prime choices out of from the screener.

    Simply Wall St Value Rating: ★★★★★☆

    Overview: Amanat Holdings PJSC, along with its subsidiaries, focuses on investing in education and healthcare companies both within the United Arab Emirates and internationally, with a market capitalization of AED3.23 billion.

    Operations: Amanat Holdings derives its revenue primarily from investments in the education and healthcare sectors, generating AED495.94 million and AED380.40 million, respectively. The company’s net profit margin is a key indicator to consider when evaluating its financial performance.

    Amanat Holdings PJSC, a relatively compact player in its field, has shown impressive earnings growth of 330% over the past year, significantly outpacing the Diversified Financial industry average of 16%. Despite this surge, a large one-off gain of AED 68.3M has influenced recent financial results. The company boasts more cash than total debt and maintains interest coverage comfortably. Its price-to-earnings ratio stands at 15.3x, slightly below the industry average of 15.6x, suggesting potential value for investors. However, Amanat’s debt to equity ratio rose from 2.8% to 10.9% over five years, indicating increased leverage concerns amidst its profitability streaks.

    Continue Reading

  • Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA USA – English USA – English

    STOCKHOLM, Jan. 26, 2026 /PRNewswire/ — BioArctic AB’s (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous autoinjector (SC-AI) as a weekly starting dose has been granted Priority Review by the U.S. Food and Drug Administration (FDA). Leqembi is indicated for the treatment of Alzheimer’s disease in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early Alzheimer’s disease). A Prescription Drug User Fee Act (PDUFA) action date is set for May 24, 2026. If approved, Leqembi Iqlik would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease.

    Should the FDA approve the Leqembi Iqlik 500 mg subcutaneous (SC) dosing regimen (two 250 mg injections), the autoinjector could be used to administer a once-weekly starting dose, as an alternative to the current bi-weekly intravenous (IV) dosing. This would enable patients and care partners to choose SC administration at home for both treatment initiation and the currently approved maintenance therapy (360 mg), offering the option of SC or IV administration throughout the entire treatment journey. The injection time for each Leqembi Iqlik autoinjector takes approximately 15 seconds per each 250 mg injection. The SC formulation also has the potential to reduce healthcare resources associated with IV dosing, such as infusion preparation and nurse monitoring, while streamlining the overall Alzheimer’s disease treatment pathway.

    The sBLA is supported by data evaluating SC administration of lecanemab across a range of doses and as part of sub-studies within the Phase 3 Clarity Alzheimer’s disease open-label extension (OLE) following the 18-month core study in individuals with early Alzheimer’s disease. Data show that once-weekly administration of the 500 mg of SC-AI achieved equivalent exposure to once every two weeks IV administration and similar clinical and biomarker benefits. SC administration demonstrated a safety profile similar to IV administration, with less than 2% incidence of systemic injection or infusion-related reactions.

    Alzheimer’s disease is a progressive, relentless disease, with amyloid beta (Aβ) and tau as hallmarks, that is caused by a continuous underlying neurotoxic process driven by protofibrils* (PF) that begins before amyloid plaque removal and continues afterward[1],[2],[3]. Only Leqembi fights Alzheimer’s disease in two ways – targeting both PF and amyloid plaque, which can impact tau downstream.

    Please see full Prescribing Information for Leqembi in the US, including Boxed WARNING.

    This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on January 26, 2026, at 00:30 CET.

    For further information, please contact: 
    Oskar Bosson, VP Communications and Investor Relations
    E-mail: [email protected]
    Telephone: +46 704 107 180

    Jenny Ljunggren, External Communications and Investor Relations Manager
    E-mail: [email protected]
    Telephone: +46 76 013 86 08

    About lecanemab (Leqembi®)
    Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

    Lecanemab is approved in 53 countries and is under regulatory review in 7 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in the United Kingdom, China, the U.S. and other countries, and applications have been filed in 4 countries and regions. In the U.S., Leqembi Iqlik™ is approved for subcutaneous dosing with an autoinjector for maintenance treatment of early Alzheimer’s disease (AD). In November 2025, a rolling sBLA application to the U.S. FDA for the subcutaneous initiation dosing with Leqembi Iqlik was also completed and a new drug application for subcutaneous formulation of Leqembi was submitted in Japan. In December 2025, Lecanemab has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China. 

    Since July 2020, Eisai’s Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer’s disease meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer’s Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S., funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

    About the collaboration between BioArctic and Eisai
    Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer’s disease. The most important agreements are the Development and Commercialization agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody Leqembi back-up for Alzheimer’s disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer’s disease. BioArctic has the right to commercialize lecanemab in the Nordic region and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer’s disease and is entitled to payments in connection with sales milestones as well as royalties on global sales.

    About BioArctic AB
    BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world’s first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer’s disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson’s disease and ALS as well as additional projects against Alzheimer’s disease. Several of the projects utilize the company’s proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic’s B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

    [1] Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z.

    [2] Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer’s Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.

    [3] Hampel H, Hardy J, Blennow K, et al. The amyloid-β pathway in Alzheimer’s disease. Mol Psychiatry. 2021;26(10):5481-5503.

    This information was brought to you by Cision http://news.cision.com

    https://news.cision.com/bioarctic/r/leqembi–iqlik—lecanemab-irmb–supplemental-biologics-license-application-regarding-subcutaneous-s,c4297439

    The following files are available for download:

    Continue Reading

  • A global markets correction may be coming, warn veterans

    A global markets correction may be coming, warn veterans

    Continue Reading

  • Needham Reiterates Buy on Docebo Inc. (DCBO), Sees Significant Upside From Current Levels

    Needham Reiterates Buy on Docebo Inc. (DCBO), Sees Significant Upside From Current Levels

    We recently published an article titled 9 High Growth Canadian Stocks to Buy. 

    Another high-growth Canadian stock to buy, Docebo Inc. (NASDAQ:DCBO) is an education technology company established in 2005. The company is known for Docebo Learn, its core learning management system offering. Docebo lists its shares on both the Toronto Stock Exchange and the Nasdaq Global Select Market.

    On January 20, Needham analyst reiterated a Buy rating on Docebo Inc. (NASDAQ:DCBO) and set a price target of $38.00. Overall analyst sentiment on the stock remains highly positive, with a Strong Buy consensus and an average price target of $35.33, implying upside potential of roughly 84%. Craig-Hallum has also reaffirmed its Buy rating on the shares.

    During its Q3 2025 earnings call, Docebo Inc. (NASDAQ:DCBO) highlighted plans to continue growing its base of customers generating more than $100,000 in annual contract value, underscoring solid momentum across the enterprise and mid-market segments. Management pointed to notable new customer wins such as Veolia, alongside expanded adoption within existing clients, including Amazon, as evidence of sustained demand and deeper platform penetration.

    Docebo Inc. (NASDAQ:DCBO) also announced the introduction of a credit-based pricing model for its AI-powered modules, including AI Virtual Coach and AI Video Presenter. This approach not only enhances flexibility for customers but also creates a clear pathway for incremental monetization over time, while reinforcing Docebo’s broader strategy of embedding artificial intelligence more deeply across its product suite.

    While we acknowledge the potential of DCBO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

    READ NEXT: 13 Best Dividend Kings to Buy in 2026 and 14 Best Mid Cap Dividend Aristocrat Stocks to Buy Now

    Disclosure: None.

    Continue Reading